Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes

Diabetes Care

Volumn 38, Issue 9, 2015, Pages 1673-1679

  Yamazaki, Hajime ^a   Tsuboya, Toru ^b,c   Tsuji, Kunihiko ^a   Dohke, Mitsuru ^d   Maguchi, Hiroyuki ^a  

^a TEINE KEIJINKAI HOSPITAL   (Japan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TOHOKU UNIVERSITY   (Japan)

^d Maruyama Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; EXERCISE; FAMILY HISTORY; FEMALE; GENDER; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDIABETIC STATE; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDIABETIC STATE; RISK FACTORS;

EID: 84962469252     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0140     Document Type: Article

References (40)

1. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013;98:483-495.
2. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis 2015;47:181-190.
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.
4. Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol 2014;8:487-500.
5. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-910.
6. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-1383.
7. Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013;28:142-147.
8. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study. Arch Med Res 2013;44:115-120.
9. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013;108:1861-1868.
10. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-729.
11. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med 2008;25:476-481.
12. Shibata M, Kihara Y, Taguchi M, Tashiro M, OtsukiM. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30:2940-2944.
13. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22:1086-1091.
14. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003;13:15-21.
15. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013;98:3637-3643.
16. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59:859-871.
17. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
18. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384.
19. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia- Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-777.
20. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010;52:370-381.
21. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-15.
22. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649-1657.
23. Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-2395.
24. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006;44:1196-1207.
25. Bertolotti M, Lonardo A, Mussi C, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol 2014;20:14185-14204.
26. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol 2000;15:775-782.
27. Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol 2012;18:3492-3501.
28. Loria P, Adinolfi LE, Bellentani S, et al.; NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-282.
29. Waki K, Noda M, Sasaki S, et al.; JPHC Study Group. Alcohol consumption and other risk factors for self-reported diabetes among middleaged Japanese: A population-based prospective study in the JPHC study cohort I. Diabet Med 2005;22:323-331.
30. Jin YJ, Kim KM, Hwang S, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors. J Gastroenterol Hepatol 2012;27: 1341-1347.
31. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103-107.
32. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43: 1060-1066.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
34. Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med 2014;53:1401-1406.
35. Sinn DH, Gwak GY, Park HN, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in nonobese, non-diabetic middle-aged Asian adults. Am J Gastroenterol 2012;107:561-567.
36. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109.
37. Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: A novel approach to reduce cardiovascular risk? Arch Med Res 2011;42:337-353.
38. Eguchi Y, Hyogo H, Ono M, et al.; JSGNAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study. J Gastroenterol 2012;47:586-595.
39. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J Hepatol 2009;51:1061- 1067.
40. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41: 1313-1321.